• br Introduction Adenosine deaminase ADA which can catalyze t

  2024-01-18

  

  Introduction Adenosine deaminase (ADA), which can catalyze the conversion of AD to inosine by removing an amino group, is a key hydrolytic enzyme of purine metabolism (Conway and Cooke, 1939), and plays an important role in an amount of diseases. For example, an increase of ADA activity in serum

• Oxamic acid mg br Funding br Introduction l Dihydroxyphenyla

  2024-01-18

  

  Funding Introduction l-3,4-Dihydroxyphenylalanine (l-DOPA) is the gold-standard treatment for the motor symptoms of Parkinson's disease (PD); however, its chronic use induces severe motor complications that eventually limit its long-term efficacy (Bastide et al., 2015). The most disabling side

• gonadotropin releasing hormone receptor No starting dose adj

  2024-01-17

  

  No starting dose adjustment is needed for mild or moderate renal impairment and mild hepatic impairment (Child-Pugh A classification) though use in patients with severe hepatic impairment (Child-Pugh classification Class C, 10–15 points score) is not recommended.8, 9, 10, 13 Drug interaction & ad

• br Acknowledgments br Introduction Angiotensin II AngII is a

  2024-01-17

  

  Acknowledgments Introduction Angiotensin II (AngII) is among the most potent vasoactive substances produced in humans. Its effects are numerous, from vasoconstriction to control of fluid and electrolytes balances. Many of the physiological and pathological effects of AngII are mediated by the

• Rp-8-Br-PET-cGMPS Several mechanisms of Cd induced carcinoge

  2024-01-17

  

  Several mechanisms of Cd-induced carcinogenicity have been reported and are comprehensively summarized by Hartwig [32]. As early as 1980, basic science studies supported a role for endocrine disruption of AR by Cd. Donovan et al. [33], using extracts of mouse prostate cytosol, showed Cd to be the mo

• br Obstructing SNARE zippering Sharma et

  2024-01-17

  

  Obstructing SNARE “zippering” Sharma et al. demonstrated for the first time that in the postmortem AD brains, the level of SNARE complex formation, which is necessary for driving synaptic vesicle fusion at the presynaptic active zone, is significantly reduced [123]. In the absence of changes in e

• br Results We set out

  2024-01-17

  

  Results We set out to identify in an unbiased manner a set of candidate “scaling factors” that might participate in transcription-dependent synaptic scaling up. The ex vivo slice and profiling studies were conducted on HsCt5 mice (described later) at postnatal day (P) 14 to P15, an age at which s

• Imatinib was first approved for the treatment

  2024-01-17

  

  Imatinib was first approved for the treatment of Philadelphia chromosome positive chronic myelogenous leukemia in 2001 [25]. This first approved small molecule antagonist is quite unusual in that it provides a durable response that lasts for more than a decade in the majority of patients. Imatinib h

• Similarly compound was prepared from

  2024-01-17

  

  Similarly, Dihydroartemisinin receptor 13 was prepared from aldehyde 8d by following similar procedures (Scheme 3). Condensation of 13 with 7b or 7e provided the corresponding amides 9j or 9k, which then went through O-debenzylation by BCl3 to deliver the final compounds 10j and 10k in 37% and 32%

• br Acetaldehyde One of the most common

  2024-01-17

  

  Acetaldehyde One of the most common environmental aldehydes is acetaldehyde (CH2CHO). Acetaldehyde, which is highly volatile, has been classified as a Group I human carcinogen by the International Agency for Research on Cancer [30]. Aldehydes can form DNA adducts, including ring-open forms of cro

• The extent to which GPCR oligomerization is a regulated

  2024-01-17

  

  The extent to which GPCR oligomerization is a regulated process still remains unclear. Reported effects of ligands on both GPCR homo- and heteromers are highly variable and depend on GPCR subtypes and the specific ligand used. According to our data, chronic treatment of mice with both paroxetine or

• For the NSCLC patients with EGFR activating mutations EGFR

  2024-01-16

  

  For the NSCLC patients with EGFR-activating mutations, EGFR-TKIs (gefitinib and erlotinib) are effective clinical therapies [21], [22]. However, approximately 10% of patients harboring EGFR-sensitizing mutations exhibit intrinsic resistance, and up to 40% do not attain a major response to treatment

• br Materials and methods br Results br

  2024-01-16

  

  Materials and methods Results Discussion Human MutL-family complexes (MutLα: MLH1-PMS2, MutLβ:MLH1-PMS1, MutLγ:MLH1-MLH3) exhibit multiple molecular activities including DNA binding, DNA cleavage, ATP binding and hydrolysis [43]. In our recent study, we have uncovered an important function

• Introduction An association of elevated branched

  2024-01-16

  

  Introduction An association of elevated branched-chain R 59-022 (BCAA—Leu, Val, Ile) with obesity and insulin resistance was first reported nearly 50 years ago (Felig et al., 1969). With the advent of metabolomics technologies, it has since become apparent that the association of BCAA and related

• gap junction Herbal medicines have been used to treat variou

  2024-01-16

  

  Herbal medicines have been used to treat various types of diseases and disorders for thousands of years worldwide (Li and Brown, 2009). Natural products have been the remedy of cancer chemotherapy for the past several decades. Anisomeles indica (L.) Kuntze. (Labiatae), commonly known as 'yu-chen-tsa

14612 records 160/975 page Previous Next First page 上5页 156157158159160 下5页 Last page